Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (May 2024)
45 slides from Curis's investor presentation, May 2024
Slide 1: Corporate Presentation May 2024
Corporate Presentation May 2024
Slide 2: Cautionary note regarding forward looking statements and disclaimers
Cautionary note regarding forward looking statements and disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “beli
Slide 3: Curis is developing the first-in-class IRAK4 inhibitor
Curis is developing the first-in-class IRAK4 inhibitor Curis Overview • Originator of the first Hedgehog inhibitor, Demonstrated single-agent licensed to Roche/Genentech , marketed as activity and safety vismodegib (Erivedge®) in NHL and AML • Emavusertib, the most advanced IRAK4 inhibitor is in Pha
Slide 4: BCR, TLR, and FLT3 Pathways are activated in heme malignancies
BCR, TLR, and FLT3 Pathways are activated in heme malignancies In NHL, In AML, BCR and TLR pathways TLR and FLT3 pathways drive NF-ĸB drive NF-ĸB (and lymphoma) (and leukemia) emavusertib emavusertib + BTKi combo emavusertib binds to IRAK4 and BTK, binds to IRAK4 and FLT3, blocking TLR and BCR pathw
Slide 5: Summary Snapshot of Clinical Data
Summary Snapshot of Clinical Data R/R NHL R/R SFm AML R/R FLT3m AML CR Rate CR + CRh/CRi Rate CR + CRh/CRi Rate 70% emavusertib 20% 35% emavusertib + ibrutinib 60% 30% emavusertib 15% 50% 25% benchmark 40% 20% 10% 30% 15% 20% ibrutinib benchmark 10% 5% 10% 5% benchmark 0% 0% 0% 1) ibrutinib USPI, 2)
Slide 6: Market Opportunity
Market Opportunity Significant market opportunities in current development programs PCNSL FLT3m SFm AML US Incidence per 100K 0.51 1.32 0.63 4.24 Newly Diagnosed Patients Per Year US 1,7001 6,0002 2,7003 20,0004 Big 5 Europe/Canada 1,8001 5,2005 2,3003 17,0005 Japan/China 7,7001 12,7005 5,6003 41,20
Slide 7: NHL Biology: IRAK4 is a novel target
NHL Biology IRAK4 is a novel target
Slide 8: Mechanism in Lymphoma
Mechanism in Lymphoma Two pathways drive NF-ĸB BCR Pathway TLR Pathway B cell TLR1 TLR2 TLR4 TLR5 (which drives B-cell lymphomas) receptor TLR6 Endosome IRAK4i + BTKi enables dual blockade of NF-ĸB TLR7 TLR8 TLR9 ibrutinib BTK Myddosome CARD11 MYD88 MALT1 BCL10 IRAK1 IRAK4 emavusertib NF-κB overacti
Slide 9: IRAK4i is synergistic with BTKi (ibrutinib)
IRAK4i is synergistic with BTKi (ibrutinib) Monotherapy vs. Combination 1400 vehicle emavusertib + ibrutinib 1200 Mean Tumor Volume (mm3) + SEM blocking both BCR and TLR pathways 1000 has been demonstrated to be better 800 ibrutinib emavusertib than blocking either one alone 600 400 emavusertib • IR
Slide 10: Preclinical support for PCNSL
Preclinical support for PCNSL IRAK4 is emavusertib demonstrated highly expressed in PCNSL extended survival in PCNSL models CA-4948 Med. Survival IRAK4 Expression in PCNSL % survival in PCNSL vehicle 44.0 days p=0.010 p=0.021 100 100% – 50 mg/kg 47.0 days 100 mg/kg Median survival 74.0 days % surviv
Slide 11: Additional NHL indications of interest
Additional NHL indications of interest CLL Waldenström's Macroglobulinemia • TLR signaling is highly activated in lymph node–resident CLL cells1 • MYD88 and CXCR4 mutations activate NF-ĸB through the TLR signature TLR pathway Lymph Node Peripheral Blood “maximal inhibition only • Recurring mutations
Slide 12: Emavusertib in Lymphoma
Emavusertib in Lymphoma a CUS’
Slide 13: Strategy in Lymphoma
Strategy in Lymphoma ❶ Demonstrate safety 19 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinibn ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to
Slide 14: Emavusertib safety profile in Lymphoma
Emavusertib safety profile in Lymphoma1 • 19 patients treated with emavusertib in 100 mg 200 mg 300 mg Total Grade 3+ TRAE in BID+IBR BID+IBR BID+IBR combination with ibrutinib in multiple NHL (N=2) (N=10) (N=7) (N=19) >1 Patient subtypes n (%) n (%) n (%) n (%) • Shown to be well tolerated with an
Slide 15: Strategy in Lymphoma
Strategy in Lymphoma ❶ Demonstrate safety 19 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinib ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to 4
Slide 16: Single-agent activity demonstrated with emavusertib
Single-agent activity demonstrated with emavusertib Percent Change in Tumor Burden from Baseline Dose Response in WM at Multiple Dose Levels 50 (6 patients treated for ~ 1 year or longer) mg 100 mg 2950 200 2850 mg 2750 2650 2550 2450 2350 2250 2150 2050 1950 IgM (mg/dL) 1850 1750 300 1650 mg 1550 1
Slide 17: Strategy in Lymphoma
Strategy in Lymphoma ❶ Demonstrate safety 19 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinib ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to 4
Slide 18: Combination data released at ASH 2023
Combination data released at ASH 2023 All patients (n=19), multiple types of B-cell lymphoma No Prior BTKi Failed Prior BTKi • Heavily pre-treated patients 0% MZL sCNS CLL MCL MCL WM WM MZL-N pCNS FL MZL-N pCNS pCNS pCNS pCNS -10% (1-10 prior lines) % Change in Marrow Blast vs. Baseline -20% -30% -4
Slide 19: PCNSL selected for lead indication in NHL
PCNSL selected for lead indication in NHL CR Rate in R/R NHL 70% emavusertib initial data compared 60% + ibrutinib favorably to ibrutinib 50% All 5 PCNSL patients monotherapy 40% PCNSL CR Rate failed prior BTKi 30% 3 of 5 (60%) 20% ibrutinib monotherapy 10% 0% Study month 1) ibrutinib USPI, 2) Wilso
Slide 20: PCNSL patient who achieved CR
PCNSL patient who achieved CR Feb 2023 enrolled in study May 2023 achieved CR Nov 2022 June 2023 relapsed on ibrutinib CR patient remains in CR Previous treatments: as of April 2024 MATRIX, HD BCNU/thiotepa-ASCT, whole brain radiation, ibrutinib 20
Slide 21: Summary in Lymphoma
Summary in Lymphoma Lymphoma • Anti-cancer activity in R/R PCNSL exceeded benchmark response criteria with potential for best-in-class therapy • Continue enrolling in combination study of emavusertib + ibrutinib in R/R PCNSL • Prioritize additional lymphoma indications that could benefit from dual-b
Slide 22: AML Biology: IRAK4 is a novel target
AML Biology IRAK4 is a novel target
Slide 23: Among innate immune and NF-ĸB signaling genes driving AML, IRAK-L is highly significant
Among innate immune and NF-ĸB signaling genes driving AML, IRAK-L is highly significant “The magnitude of IRAK4 isoform switching was highly significant among AML samples and the inclusion of exon 4 alone correlated with worse outcome” Exon architecture of IRAK4 and protein domains. Sashimi plots re
Slide 24: Preclinical experiments demonstrated IRAK4-L to be a powerful driver of AML
Preclinical experiments demonstrated IRAK4-L to be a powerful driver of AML Knocking out IRAK4 stops leukemic activity (similar findings using CRISPR/CAS9) Control Smith Nat Cell Biol. 2019 adding back IRAK4-L restarts activity adding back IRAK4-S has no effect Smith Nat Cell Biol. 2019 24
Slide 25: Emavusertib specific design
Emavusertib specific design emavusertib was selected by NCI for its sponsored research and clinical studies of IRAK4 Emavusertib Emavusertib Kinase Interaction Map Binding Affinity FLT3 Target Kd nM IRAK4 IRAK1 12,000 binds tightly to IRAK4 IRAK2 >20,000 IRAK3 8,500 IRAK4 23 DYRK1A 25 CLK 1, 2, 4 FL
Slide 26: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim Leukemia Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path t
Slide 27: Emavusertib safety profile in Leukemia
Emavusertib safety profile in Leukemia1 200 mg BID 300 mg BID 400 mg BID 500 mg BID Total Grade 3+ TRAE > 1 patients (N = 27) (N = 78) (N = 15) (N = 3) (N=123) • 123 patients treated with n (%) n (%) n (%) n (%) n (%) emavusertib in AML Number of patients having 4 (14.8) 21 (26.9) 7 (46.7) 2 (66.7)
Slide 28: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim Leukemia Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path t
Slide 29: Emavusertib in SFm AML
Emavusertib in SFm AML a CUS’
Slide 30: Mechanism in SFm AML
Mechanism in SFm AML Spliceosome Ex3 U2AF1 mutation splicing mutations are a driver of IRAK4-L Ex4 Ex5 (enriching for SFm, enriches for high IRAK4-L) Ex4 IRAK4-L drives Myddosome constitutive activation MYD88 of the myddosome IRAK4-Long emavusertib NF-ĸB overactivity Smith et al. Nat Cell Biol. 2019
Slide 31: R/R SFm AML anti-cancer activity supports combination
R/R SFm AML CR + CRh/CRi Rate 20% 15% Benchmark for SFm AML anti-cancer activity 0% CR/CRi 10% supports combination R/R sAML with aza+ven1 CR/CRi approach - Tet2 86% - Favorable risk 75% 5% - Intermediate risk 65% - Adverse-risk 34% - U2AF1 0% 0% aza-ven emavusertib 1) Aldoss Am J Hem 2019 [CR/CRi];
Slide 32: R/R SFm AML anti-cancer activity supports combination approach
R/R SFm AML anti-cancer activity supports combination approach Benchmark for SFm Clinical Observations in Ongoing Patients 2 mo. survival 8 patients 1.0 ongoing who have not yet achieved CR/CRh Duration on Treatment CR 0.8 ongoing CRh → neutrophils up 49%, platelets > 100,000 ongoing → (meets ANC re
Slide 33: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim Leukemia Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path t
Slide 34: Emavusertib in FLT3m AML
Emavusertib in FLT3m AML a CUS’
Slide 35: IRAK4 inhibition overcomes adaptive resistance to FLT3i
Emavusertib’s dual-targeting of IRAK4 and FLT3 offers opportunity in FLT3m AML IRAK4i synergy with FLT3 inhibition 100% – 75% – IRAK4 inhibition FLT3i Control overcomes adaptive resistance 50% – IRAKi to FLT3i 25% – FLT3i + 0% – IRAKi 0 2 4 6 8 10 Days Percent viable cells in preclinical AML cell li
Slide 36: Potential Best-in-class R/R FLT3m AML
R/R FLT3m AML CR + CRh/CRi Rate Potential 35% Best-in-class 30% 25% Benchmark for FLT3m AML 20% 9 of 12 patients 21% CR/CRh had progressed following prior FLT3i 15% 87% of patients in benchmark study 10% were naïve to FLT3i3 5% 0% venetoclax azacitidine gilteritinib emavusertib 1) Konopleva Cancer D
Slide 37: Potential Best-in-class R/R FLT3m AML
R/R FLT3m AML Potential Best-in-class Duration on Treatment CR CR MLFS went to SCT CR → went to SCT ongoing CRh → 3 of 3 patients naïve to FLT3i achieved objective response ongoing → MLFS → 3 of 8 patients who had progressed following prior FLT3i achieved objective response ongoing ongoing → Not Eva
Slide 38: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim Leukemia Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path t
Slide 39: Emavusertib in All Comers
Emavusertib in All Comers a CUS’
Slide 40: Combination approach to target all comers in AML
Combination approach to target all comers in AML IRAK4-L is expressed emavusertib was active emavusertib’s novel MOA in nearly all AML patients even in non-targeted patients was synergistic with aza/ven 800 31 AML patients Preclinical Data without SF or FLT3 mutation All Comers Model Relative cell g
Slide 41: Summary in AML
Summary in AML Leukemia • Single-agent activity in FLT3m meets CR/CRh criteria reported for approved therapies, shows potential for best-in-class therapy • Observed anti-cancer activity suggests potential for add-on to combination therapy (SFm) st • Potential for rapid path to 1 label in R/R AML for
Slide 42: Other Information
Other Information a CUS’
Slide 43: Financials and IP
Financials and IP As of March 31, 2024 $40.7M Cash and investments (Estimated runway into 2025) ~5.9M Shares Outstanding We believe cash is sufficient to achieve anticipated milestones ~7.0M Shares Fully Diluted • Lymphoma data late-2024 • AML triplet data late-2024 2035 Composition of Matter IP on
Slide 44: Curis is developing the first-in-class IRAK4 inhibitor
Curis is developing the first-in-class IRAK4 inhibitor Curis Overview • Originator of the first Hedgehog inhibitor, Demonstrated single-agent licensed to Roche/Genentech , marketed as activity and safety vismodegib (Erivedge®) in NHL and AML • Emavusertib, the most advanced IRAK4 inhibitor is in Pha
Slide 45: End of Presentation
End of Presentation a CUS’